Becton, Dickinson and Company (NYSE:BDX) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Monday. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10, FiscalAI reports. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the previous year, the business posted $3.43 earnings per share. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company updated its FY 2026 guidance to 12.350-12.650 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Closed the life sciences combination with Waters, receiving a $4.0 billion cash distribution and announcing deployment of $2.0 billion to share repurchases (ASR) and $2.0 billion to debt paydown, supporting capital returns and balance-sheet strengthening.
• Q1 revenue was $5.3 billion (up 0.4%) with New BD +2.5% and adjusted EPS $2.91 beating expectations; fiscal 2026 guidance for New BD calls for low single-digit revenue growth, ~25% adjusted operating margin, and adjusted EPS of $12.35–$12.65 (midpoint ≈ +6%).
• Commercial and innovation momentum across high-growth platforms — double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation; Pyxis Pro launch showing strong competitive conversions and BD has >80 GLP‑1 molecules contracted in delivery devices.
• Operational improvements driving margin and cash-flow — BD Excellence delivered ~8% productivity improvement this quarter, manufacturing network reduced to under 50 global sites, and $150M (75%) of a $200M cost-out program already executed.
• Headwinds remain in about 10% of the portfolio — Alaris remediation, lower vaccine demand and China VBP dynamics, plus tariffs (roughly 170 bps hit to gross margin and a material EPS drag) which management says temper near-term results.

Becton, Dickinson and Company Stock Down 1.3%

BDX stock opened at $207.31 on Tuesday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $235.34. The business has a 50-day simple moving average of $200.14 and a 200 day simple moving average of $192.53. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The company has a market cap of $59.06 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 beat — BDX reported adjusted EPS $2.91 vs. consensus ~$2.81 and revenue $5.25B, with margin improvements despite adjusted EPS being below last year, showing underlying operational strength. Becton Dickinson BDX Q1 2026 Earnings Transcript
• Positive Sentiment: Spin-off/combination closed — BD completed the combination of its Biosciences & Diagnostic Solutions business with Waters, crystallizing the company’s move to a narrower “New BD” focused on medical technology. That structural clarity can make capital allocation and valuation more straightforward. BD Completes Combination with Waters Corporation
• Positive Sentiment: Shareholder cash deployment — Management outlined $4B of cash deployment following the Waters transaction (buybacks/dividend implications), which is supportive for EPS and return of capital. BD Outlines $12.35–$12.65 EPS Guidance and $4B Cash Deployment
• Neutral Sentiment: Analyst / rating context — Some analysts see valuation and leverage as justifying a Hold; revenue restatement news hasn’t materially changed the outlook according to at least one note, leaving sentiment mixed. Analyst Note: Hold Rating, TipRanks
• Negative Sentiment: Lowered FY‑2026 EPS guidance — Management set FY‑2026 adjusted EPS for New BD at $12.35–$12.65, well below prior consensus (~$14.81), explicitly reflecting the sale/spin of the biosciences & diagnostics unit; that reduction in forward earnings is the main driver of downward pressure on the stock. Reuters: Becton Dickinson cuts annual profit forecast
• Negative Sentiment: Market reaction — Shares fell nearly 3% in early trading as the guidance cut and the transition to New BD outweighed the beat and cash plans; coverage notes the beat was overshadowed by the lowered outlook. Investing.com: Shares Fall Nearly 3%

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent research reports. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley upped their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Bank of America raised their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Jefferies Financial Group increased their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Finally, Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Five investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $213.36.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 2,463 shares of company stock valued at $501,530. 0.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Centaurus Financial Inc. grew its position in Becton, Dickinson and Company by 115.9% in the third quarter. Centaurus Financial Inc. now owns 3,767 shares of the medical instruments supplier’s stock valued at $705,000 after acquiring an additional 2,022 shares during the last quarter. Faithward Advisors LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $235,000. Coldstream Capital Management Inc. boosted its position in Becton, Dickinson and Company by 10.8% in the third quarter. Coldstream Capital Management Inc. now owns 5,400 shares of the medical instruments supplier’s stock valued at $1,011,000 after buying an additional 528 shares in the last quarter. Advisory Services Network LLC grew its stake in shares of Becton, Dickinson and Company by 9.4% during the third quarter. Advisory Services Network LLC now owns 19,086 shares of the medical instruments supplier’s stock worth $3,572,000 after buying an additional 1,637 shares during the last quarter. Finally, Hancock Whitney Corp grew its stake in shares of Becton, Dickinson and Company by 2.7% during the third quarter. Hancock Whitney Corp now owns 11,953 shares of the medical instruments supplier’s stock worth $2,237,000 after buying an additional 310 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.